Eltrombopag: A Novel Oral Thrombopoietin Receptor Agonist

Abstract

Spanish

Objective:

To review the pharmacology and pharmacokinetics and evaluate the safety and efficacy of eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP) and thrombocytopenia associated with hepatitis C virus (HCV) cirrhosis.

Data Sources:

A Cochrane Controlled Trial Register, clinicaltrials.gov, EMBASE, and MEDLINE search was performed (January 1966–March 2010) using the key terms eltrombopag and SB-497115-GR. Searches were limited to published English-language studies in humans and a reference review of the pertinent literature was conducted.

Study Selection and Data Extraction:

Published pharmacokinetic data and safety and efficacy trials, case reports, and case series on the use of eltrombopag were selected for inclusion.

Data Synthesis:

Eltrombopag is a novel second-generation thrombopoietin receptor agonist that was approved by the Food and Drug Administration for the treatment of chronic ITP in patients who had an insufficient response to corticosteroids, intravenous immune globulin, or splenectomy. Eltrombopag has been shown to be superior to placebo in increasing platelet counts, with more patients achieving counts >50 × 10³/μL. One study has also shown eltrombopag to be effective in the treatment of thrombocytopenia associated with HCV cirrhosis. Eltrombopag has a boxed warning related to risk of hepatotoxicity, with criteria for discontinuation in patients with elevated liver enzyme levels or clinical signs of liver damage. As such, close monitoring of laboratory parameters is required, and patients must be registered with the PROMACTA CARES program.

Conclusions:

Eltrombopag is effective in increasing platelet counts in patients with chronic ITP and in patients with HCV cirrhosis. In the treatment of ITP, eltrombopag has been studied only for short durations and is more expensive than first-line oral corticosteroids; therefore, it should be considered a second-tine agent. More studies are needed to identify a place in therapy for eltrombopag in the treatment of thrombocytopenia associated with HCV cirrhosis.

Keywords

cirrhosis eltrombopag hepatitis C virus idiopathic thrombocytopenic purpura immune thrombocytopenic purpura

Get full access to this article

View all access options for this article.

References

Cines

, Blanchette

. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995–1008.

Seagal

, Powe

. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost 2008;4:2377–83.

Fuedjo-Tepie

, Robinson

, Bennett

Prevalence of diagnosed chronic immune thrombocytopenic purpura in the US: analysis of a large US claim database: a rebuttal. J Thromb Haemost 2008;6:711–2.

George

, Woolf

, Raskob

. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3–40.

Kuter

. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med 2009;60:93–206.

McHutchison

, Dusheiko

, Shiftman

. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007;357:2227–36.

GlaxoSmithKline. Eltrombopag treatment of thrombocytopenia in subjects with advanced myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia after MDS (sAML/MDS). Clinicaltrials.gov Identifier: NCT00903422. http://clinicaltrials.gov/ct2/show/NCT00903422. (accessed 2010 Mar 17).

Jenkins

, Williams

, Deng

. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007;109:4739–41.

Product Information. PROM ACTA (eltrombopag). Research Triangle Park, NC: GlaxoSmithKline, October 2008. www.promactacares.com/prescribing_inforrnation.pdf (accessed 2009 Dec 20).

10.

Erhardt

, Erickson-Miller

, Aivado

. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function. Exp Hematol 2009;37:1030–7.

11.

Bussel

, Cheng

, Saleh

. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl S Med 2007;357: 2237–47.

12.

Bussel

, Provan

, Shamsi

. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:641–8.

13.

Bussel

, Psaila

, Saleh

. Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic idiopathic thrombocytopenic purpura (abstract 3431). Blood 2008;112:1176.

14.

Cheng

, Saleh

, Bussel

. Oral eltrombopag for the long-term treatment of patients with chronic idiopathic thrombocytopenic purpura: results of a phase III, double-blind, placebo-controlled study (RAISE) (abstract 400). Blood 2008; 112:400. Presented at: 50th annual meeting of the American Society of Hematology, San Francisco, CA, December 6-9,2008.

15.

Bussel

, Cheng

, Saleh

. Safety and efficacy of long-term treatment with oral eltrombopag for chronic idiopathic thrombocytopenic purpura (abstract 3432). Blood 2008;112:1177. Presented at: 50th annual meeting of the American Society of Hematology, San Francisco, CA, December 6-9,2008.

16.

Afdhal

, McHutchison

, Brown

. Thrombocytopenia associated with chronic liver disease. J Hepatol 2008;48:1000–7.

17.

Will

, Kawahara

, Luciano

. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood 2009;114:3899–908.

18.

Jenkins

, Williams

, Deng

. Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis. Eur J Clin Pharmacol 2010; 66:67-76.

19.

Williams

, Peng

, Bailey

. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clin Ther 2009;31:764–76.

20.

PROMACTA CARES Overview for Healthcare Providers, www.promactacares.com (accessed 2009 Jan 22).

21.

George

, Woolf

, Raskob

. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996;88:3–40.

22.

British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children, and pregnancy. Br J Haematol 2003;120:574–96.

23.

Cohen

, ed. Drug topics red book. Montvale, NJ: Thomson PDR, 2009.